These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 24201742)

  • 1. Anti-cytokeratin CAM5.2 recognized CK8 mainly, but not CK18: comment on "Early assessment of axillary response with 18F-FDG PET/CT during neoadjuvant chemotherapy in stage II-III breast cancer: implications for surgical management of the axilla. Annals of Surgical Oncology doi: 10.1245/s10434-013-2902-0 (2013)".
    Chao WR; Han CP
    Ann Surg Oncol; 2014 Feb; 21(2):699. PubMed ID: 24201742
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply to "Anti-cytokeratin CAM5.2 recognized CK8 mainly, but not CK18: comment on 'Early assessment of axillary response with 18F-FDG PET/CT during neoadjuvant chemotherapy in stage II-III breast cancer: implications for surgical management of the axilla. Ann Surg Oncol. 2013;20(7):2227-35'".
    Koolen BB; Wesseling J
    Ann Surg Oncol; 2014 Feb; 21(2):700. PubMed ID: 24052316
    [No Abstract]   [Full Text] [Related]  

  • 3. Early assessment of axillary response with ¹⁸F-FDG PET/CT during neoadjuvant chemotherapy in stage II-III breast cancer: implications for surgical management of the axilla.
    Koolen BB; Valdés Olmos RA; Wesseling J; Vogel WV; Vincent AD; Gilhuijs KG; Rodenhuis S; Rutgers EJ; Vrancken Peeters MJ
    Ann Surg Oncol; 2013 Jul; 20(7):2227-35. PubMed ID: 23456316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Level III axillary lymph nodes involvement in node positive breast cancer received neoadjuvant chemotherapy.
    Fan Z; Li J; Wang T; Xie Y; Fan T; Lin B; Ouyang T
    Breast; 2013 Dec; 22(6):1161-5. PubMed ID: 24080493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thin-section CT evaluation and pathologic correlation of therapeutic effect of neoadjuvant chemotherapy for axillary lymph nodes of clinically node-positive breast cancer patients.
    Ogawa Y; Nishioka A; Nishigawa T; Kubota K; Kariya S; Yoshida S; Tanaka Y; Moriki T; Tochika N
    Oncol Rep; 2003; 10(4):985-9. PubMed ID: 12792757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive value of FDG PET/CT for pathologic axillary node involvement after neoadjuvant chemotherapy.
    Keam B; Im SA; Koh Y; Han SW; Oh DY; Cho N; Kim JH; Han W; Kang KW; Moon WK; Kim TY; Park IA; Noh DY; Chung JK; Bang YJ
    Breast Cancer; 2013 Apr; 20(2):167-73. PubMed ID: 22311581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of the axilla after neoadjuvant chemotherapy for clinically node positive breast cancer: A nationwide survey study in The Netherlands.
    Vugts G; Maaskant-Braat AJ; de Roos WK; Voogd AC; Nieuwenhuijzen GA
    Eur J Surg Oncol; 2016 Jul; 42(7):956-64. PubMed ID: 27107791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Marking axillary lymph nodes with radioactive iodine seeds for axillary staging after neoadjuvant systemic treatment in breast cancer patients: the MARI procedure.
    Donker M; Straver ME; Wesseling J; Loo CE; Schot M; Drukker CA; van Tinteren H; Sonke GS; Rutgers EJ; Vrancken Peeters MJ
    Ann Surg; 2015 Feb; 261(2):378-82. PubMed ID: 24743607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined PET-CT and axillary lymph node marking with radioactive iodine seeds (MARI procedure) for tailored axillary treatment in node-positive breast cancer after neoadjuvant therapy.
    Koolen BB; Donker M; Straver ME; van der Noordaa MEM; Rutgers EJT; Valdés Olmos RA; Vrancken Peeters MJTFD
    Br J Surg; 2017 Aug; 104(9):1188-1196. PubMed ID: 28524246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pre-chemotherapy 18F-FDG PET/CT upstages nodal stage in stage II-III breast cancer patients treated with neoadjuvant chemotherapy.
    Koolen BB; Valdés Olmos RA; Vogel WV; Vrancken Peeters MJ; Rodenhuis S; Rutgers EJ; Elkhuizen PH
    Breast Cancer Res Treat; 2013 Sep; 141(2):249-54. PubMed ID: 24002735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy.
    Keam B; Im SA; Kim HJ; Oh DY; Kim JH; Lee SH; Chie EK; Han W; Kim DW; Cho N; Moon WK; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    Breast Cancer Res Treat; 2009 Jul; 116(1):153-60. PubMed ID: 18787948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Marking the axilla with radioactive iodine seeds (MARI procedure) may reduce the need for axillary dissection after neoadjuvant chemotherapy for breast cancer.
    Straver ME; Loo CE; Alderliesten T; Rutgers EJ; Vrancken Peeters MT
    Br J Surg; 2010 Aug; 97(8):1226-31. PubMed ID: 20602508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 18F-fluorodeoxyglucose (FDG) PET/CT after two cycles of neoadjuvant therapy may predict response in HER2-negative, but not in HER2-positive breast cancer.
    Cheng J; Wang Y; Mo M; Bao X; Zhang Y; Liu G; Zhang J; Geng D
    Oncotarget; 2015 Oct; 6(30):29388-95. PubMed ID: 26336821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Noninvasive nodal restaging in clinically node positive breast cancer patients after neoadjuvant systemic therapy: a systematic review.
    Schipper RJ; Moossdorff M; Beets-Tan RGH; Smidt ML; Lobbes MBI
    Eur J Radiol; 2015 Jan; 84(1):41-47. PubMed ID: 25458227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Locoregional lymph node involvement on 18F-FDG PET/CT in breast cancer patients scheduled for neoadjuvant chemotherapy.
    Koolen BB; Valdés Olmos RA; Elkhuizen PH; Vogel WV; Vrancken Peeters MJ; Rodenhuis S; Rutgers EJ
    Breast Cancer Res Treat; 2012 Aug; 135(1):231-40. PubMed ID: 22872522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Sentinel lymph node biopsy after neoadjuvant chemotherapy in breast cancer].
    Mátrai Z; Tóth L; Polgár C; Láng I; Gõdény M; Sinkovics I; Horváth Z; Bidlek M; Udvarhelyi N; Bartal A; Sávolt A; Ujhelyi M; Kásler M
    Magy Onkol; 2011 Jun; 55(2):73-84. PubMed ID: 21655472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Axillary Response Monitoring After Neoadjuvant Chemotherapy in Breast Cancer: Can We Avoid the Morbidity of Axillary Treatment?
    Vugts G; Nieuwenhuijzen GA; Maaskant-Braat AJ; Schipper RJ; Smidt ML
    Ann Surg; 2016 Feb; 263(2):e28-9. PubMed ID: 25405555
    [No Abstract]   [Full Text] [Related]  

  • 18. Potential impact of 18F-FDG PET/CT on patients selection for neoadjuvant chemotherapy before radical cystectomy.
    Rouanne M; Girma A; Neuzillet Y; Vilain D; Radulescu C; Letang N; Yonneau L; Hervé JM; Botto H; Le Stanc E; Lebret T
    Eur J Surg Oncol; 2014 Dec; 40(12):1724-30. PubMed ID: 25242381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preoperative evaluation of prognosis in breast cancer patients by [(18)F]2-Deoxy-2-fluoro-D-glucose-positron emission tomography.
    Inoue T; Yutani K; Taguchi T; Tamaki Y; Shiba E; Noguchi S
    J Cancer Res Clin Oncol; 2004 May; 130(5):273-8. PubMed ID: 14986112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reply to Letter: "Response to Axillary Response Monitoring After Neoadjuvant Chemotherapy in Breast Cancer: Can We Avoid the Morbidity of Axillary Treatment?".
    Donker M; Rutgers EE; Vrancken Peeters MJ
    Ann Surg; 2016 Feb; 263(2):e29. PubMed ID: 25405561
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.